1. Home
  2. TNXP vs RDHL Comparison

TNXP vs RDHL Comparison

Compare TNXP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.56

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$1.09

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
RDHL
Founded
2007
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
5.4M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
TNXP
RDHL
Price
$13.56
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
364.8K
39.3K
Earning Date
05-11-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
$381.91
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$0.71
52 Week High
$69.65
$3.31

Technical Indicators

Market Signals
Indicator
TNXP
RDHL
Relative Strength Index (RSI) 51.84 74.01
Support Level $13.32 $1.06
Resistance Level $14.52 $1.26
Average True Range (ATR) 0.74 0.06
MACD 0.03 0.03
Stochastic Oscillator 65.08 95.31

Price Performance

Historical Comparison
TNXP
RDHL

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Share on Social Networks: